Navigation Links
ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia
Date:11/21/2008

SAN DIEGO, Nov. 21 /PRNewswire/ -- ChemDiv Inc. and Avineuro Pharmaceuticals Inc. have extended the term of their research and development collaboration including formulation, safety and early clinical development studies in areas of neurodegenerative and psychiatric disorders. R&D services will be provided by Chemical Diversity Research Institute, ChemDiv's research subsidiary based in Moscow. The new agreement provides for research funding of clinical candidate compounds to POC. Avineuro is responsible for further clinical development and commercialization of drug candidates AVN101, AVN211, and additional compounds that may be nominated for development from the ongoing research and discovery under the agreement. In September, ChemDiv entered into an out-licensing and collaboration agreement with Avineuro to develop multiple compounds for Alzheimer Disease and schizophrenia. Under the agreement, Avineuro obtained exclusive worldwide rights to clinical development candidates AVN101, AVN211, and lead compounds in various stages of pre-clinical development. ChemDiv will provide pre-clinical development services to nominate additional backup leads and candidates for Avineuro.

About Avineuro Pharmaceuticals, Inc.:

Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Founded in August 2008 and headquartered in San Diego, California, Avineuro is managed by seasoned professionals experienced in drug discovery and development. By acquiring lead compounds through collaborations and partnerships, Avineuro plans to develop novel products and extend the reach of marketed compounds for indications with a significant commercial potential. Avineuro emphasizes a rational approach that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

About ChemDiv, Inc.

ChemDiv, Inc. is a global chemistry-driven contract research organization accelerating discovery and development of novel therapies through comprehensive Discovery outSource(TM) services, including pre-clinical development, discovery biology, medicinal and synthetic chemistry.


'/>"/>
SOURCE ChemDiv, Inc.; Avineuro Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChemDiv and Achaogen Enter Into a Discovery Collaboration
2. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
3. Roche Extends Tender Offer for Ventana
4. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
5. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
6. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
7. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
8. ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook
9. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
10. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... The Council for Agricultural ... to Jayson Lusk, a consummate communicator who promotes agricultural science and technology in ... as he explains how innovation and growth in agriculture are critical for food ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... FDA’s GMP expectations for phase I clinical trials comes to Tampa, San Francisco ... biotechnology and pharma professionals representing FDA regulated organizations such as Pfizer Inc., Teva ...
(Date:4/26/2017)... 2017  Genisphere LLC, provider of the 3DNA ... collaborative and sponsored research agreement with the University ... The overall goal of the partnership is to ... designs and formulations after in vivo ... vasculature as well as inflammatory responses, demonstrating various ...
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. Robert G. ... , proudly announced today that acclaimed physiatrist Matthew Terzella, MD, has joined the ... 2017. , Dr. Terzella completed his residency in Physical Medicine and Rehabilitation at ...
Breaking Biology Technology:
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):